

Histoplasmosis in the Americas, II regional meeting

Manaus, Brazil

March 22-24th, 2019

Hotel: Tropical Executive Hotel

Av. Coronel Teixeira, 1320 Bloco A

Manaus, CEP 69029-120, Brazil

Phone: +55 92 3305-7999

Welcome to the second meeting of the international Histoplasmosis advocacy Group (iHAG), is co-organized by the Fundação de Amparo a Pesquisa do Estado do Amazonas (FAPEAM), the Pan American Health Organization (PAHO) and the Center for Disease Control and Prevention (CDC). With co-sponsorship of the Global Action Fund for Fungal Infections (GAFFI), the International Society for Human and Animal Mycology (ISHAM) and the Mycoses Study Group Education and Research Consortium (MSGERC).

The inaugural meeting in 2015 brought together colleagues from 13 different countries to discuss how to better diagnose and treat histoplasmosis. The meeting concluded with the goal of 80 by 20, striving by the year 2020 to have 80% of countries in the Americas to possess the capacity to rapidly diagnose and treat the disease.

The second meeting will focus on the status of capacity to diagnose and treat Histoplasmosis throughout the regions, as well as new developments in both laboratory and treatment options. The agenda will be composed of keynote lectures, scientific talks, country updates, and policy discussions.

We hope that many scientist, doctors and health representatives from the different countries will join iHAG this year in Manaus.



Meeting program

Day 1. March 22 th , 2019	
15:00-16:30	Meeting attendees registration
16:30-17:00	Welcome and opening plenary and officials' introduction
17:00-17:30	Lecture: Histoplasmosis state of the art and a focus on people living with HIV care and treatment
17:30-18:00	Lecture: Histoplasmosis in pediatric population with AIDS
18:00-18:20	Why are we all here? Insights in previous meetings and objectives of the present meeting.
18:20-18:40	What has been achieved since the 2015 meeting? Realizations and trends regarding HIV-associated histoplasmosis
18:40-19:00	Education and training course: what's available to date and strategies to raise awareness on histoplasmosis in the Americas and the Caribbean?
19:00-19:20	Progress and challenges to end the HIV epidemic in Latin America and the Caribbean. New opportunities to tackle advanced HIV disease, including TB-HIV co-infection and histoplasmosis.
19:00-21:00	Welcome cocktail and dinner

Countries presentations are going to be done based on the regions described below in the map



8:00-10:00	<p>Current status of diagnosis, treatment and surveillance of histoplasmosis: analysis by regions 10 min/region (speaker designated by each region)</p> <p>Regions:</p> <ul style="list-style-type: none"> • North America (Speaker to be defined) • Central America (Speaker to be defined) • The Andes (Speaker to be defined) • The Guiana Shield (Speaker to be defined) • Brazil (Speaker to be defined) • The Southern Cone (Speaker to be defined) • The Caribbean (Speaker to be defined)
10:00-10:20	Coffee break
10:20-12:30	<p>Strategies to reach the 80 by 20 objectives: diffusion of a rapid diagnostic tool</p> <ul style="list-style-type: none"> • 10:20-10:35. Diagnosis of histoplasmosis by antigen detection • 10:35-10:50. What is killing people with AIDS in 2018? Coinfections continue to remain undiagnosed killers: minimally invasive autopsy • 10:50-12:00. Technology transfer of histoplasmosis rapid diagnostic tests (RDTs): notes from the field (10 min/each) <ul style="list-style-type: none"> • FungiRed implementation in Guatemala • Multicenter study for the detection of histoplasmosis in Brazil • Implementation of a histoplasmosis RDT in Central America & Colombia • Implementation of a histoplasmosis RDT in Argentina • Multicenter study for the detection of histoplasmosis on the Guiana Shield <p>12:00-12:30. Open discussion on the barriers and opportunities regarding capacity building in the laboratory</p>
12:30-13:30	Lunch
13:30-14:30	<p>Strategies to reach the 80 by 20 objectives: improvement in effective antifungals availability in the Americas and the Caribbean</p> <ul style="list-style-type: none"> • 13:30-13:40. Update on the systematic review regarding HIV-associated histoplasmosis care and treatment • 13:40-13:50. Access to antifungals: situation analysis in Latin America <p>13:50-14:30. Open discussion on the barriers and opportunities regarding access to effective antifungals</p>
14:30-15:30	<p>Strategies to reach the 80 by 20 objective: implementation of a regional surveillance system for histoplasmosis</p> <ul style="list-style-type: none"> • 14:30-14:40. Clinical Mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities. • 14:40-14:50. Regional surveillance system proposal <p>14:50-15:30. Open discussion on the barriers and opportunities regarding the implementation of an epidemiological surveillance network</p>

15:30-15:50	Coffee break
15:50-18:00	<p>Regional SWOT analysis (Strength Weakness Opportunity Threat) on the access to diagnostic tests and effective antifungal therapy, and surveillance regarding HIV-associated histoplasmosis</p> <ul style="list-style-type: none"> • Attenders will be split in four groups, balanced by region and gender • Activity will be addressed by the SWOT coordinator • Carousel methodology in 4 groups with 4 facilitators (sub-coordinators) • Each group will discuss each one of the four SWOT categories (20 min/category)

SWOT methodology



Day 3. March 24th, 2019

8:00-9:50	Histoplasmosis RDTs to whom, when and how? <ul style="list-style-type: none">• 8:00-8:20. Clinical stewardship and algorithms proposal for the care and treatment of HIV-associated histoplasmosis. Open discussion with experts• 8:20-8:40. What can we learn from previous fungal RDTs implementation? Feedback on the cryptococcal RDTs implementation and the management of subsequent clinical situations <p>8:40-9:50. Open discussion regarding the clinical stewardship and statement of the iHAG on the clinical stewardship proposal</p>
9:50-10:00	Coffee break
10:00-12:00	Meeting conclusions and perspectives for the iHAG initiative <ul style="list-style-type: none">• 10:00-10:15. Conclusions and main trends regarding the situation analysis by region and the SWOT analysis (focus on diagnosis, treatment access and surveillance)• 10:15-10:50. Open discussion on commentaries and delivery of consensual conclusions <p>10:50-11:50. Open discussions of the “Manaus declaration”: iHAG future priorities and formulation of objectives</p>
11:50-12:00	Closing remarks on the meeting conclusions and perspectives